Scarica l'app Stockscreener
1.59
7.27%
-0.13
Proqr Therapeutics N V Borsa (PRQR) Ultime notizie
ProQR Therapeutics files prospectus for 3.03M share offering - scanx.trade
ProQR Therapeutics (PRQR) registers 3.03M shares for resale on Nasdaq - Stock Titan
ProQR prices $50M stock offering; secures $9.2M investment from Eli Lilly - MSN
ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis (NASDAQ:PRQR) - Seeking Alpha
ProQR posts early-stage trial data for liver disease candidate - MSN
Insider Buying: ProQR Therapeutics Independent Non-Executive Director Bought €231k Of Shares - simplywall.st
PRQRProQR Therapeutics N.V Options - Finviz
Bart Filius Acquires 150,000 Shares of ProQR Therapeutics NV - GuruFocus
Form 13D/A ProQR Therapeutics N.V. For: 30 June By Investing.com - Investing.com South Africa
Van Herk group reports 10.9% ProQR (PRQR) ownership after share issuances - Stock Titan
ProQR (PRQR) director receives 14,595-share option grant at $1.42 strike - Stock Titan
Director Bart Filius buys 150,000 ProQR (PRQR) Ordinary Shares in open market - Stock Titan
ProQR Therapeutics N.V. Actuals & Estimates (TRADEGATE:0PQ) - TradingView
0PQ Forecast — Price Target — Prediction for 2027 - TradingView
PRQR Maintained by Evercore ISI Group -- Price Target Raised to $6.00 - GuruFocus
Small-cap ProQR Therapeutics secures funding from Eli Lilly on early trial success - MSN
ProQR Raises $59 Million in Equity Offering and Eli Lilly Private Placement - The Globe and Mail
ProQR Therapeutics (NASDAQ: PRQR) raises capital; Lilly to purchase 5.1M shares - Stock Titan
PRQR Maintains Buy Rating by Jones Trading -- Price Target Lowered to $10.00 - GuruFocus
PRQR Maintained by Chardan Capital -- Price Target Lowered to $3 - GuruFocus
ProQR Therapeutics N.V. Actuals & Estimates (DUS:0PQ) - TradingView
ProQR Therapeutics N.V. Actuals & Estimates (NASDAQ:PRQR) - TradingView
Chardan Research Adjusts ProQR Therapeutics Price Target to $3 From $4, Maintains Buy Rating - marketscreener.com
Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success - Sahm
ProQR (PRQR) prices share offering and Eli Lilly private placement - Stock Titan
Price to book forward of ProQR Therapeutics N.V. – NASDAQ:PRQR - TradingView
Price to sales forward of ProQR Therapeutics N.V. – LS:A12B97 - TradingView
ProQR Therapeutics NV (PRQR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Enterprise value to EBIT forward of ProQR Therapeutics N.V. – LS:A12B97 - TradingView
ProQR Therapeutics NVPhase 2 Program Expec - Moomoo
ProQR Therapeutics N.V. Actuals & Estimates (MUN:0PQ) - TradingView
PRQR Forecast — Price Target — Prediction for 2027 - TradingView
ProQR Therapeutics (PRQR) Reports Progress in Phase 1 Study of A - GuruFocus
Price to earnings forward of ProQR Therapeutics N.V. – NASDAQ:PRQR - TradingView
Price to earnings forward of ProQR Therapeutics N.V. – LS:A12B97 - TradingView
ProQR Therapeutics N.V. Actuals & Estimates (LS:A12B97) - TradingView
ProQR Therapeutics (PRQR) Launches $50M Share Offering with Eli Lilly Participation - GuruFocus
ProQR Therapeutics reports positive Phase 1 data for AX-0810 RNA editing candidate - grafa.com
A12B97 Forecast — Price Target — Prediction for 2027 - TradingView
ProQR prices $50M stock offering at $1.81 per share - Investing.com UK
ProQR's $59M Raise: A Strategic Bet on RNA Editing's Future - BriefGlance
ProQR prices $50M stock offering at $1.81 per share By Investing.com - Investing.com Australia
Retinitis Pigmentosa Market Unlocking New Revenue Opportunities and Strategic Expansion by 2034 – DelveInsight | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics, 4D Molecular Therap - Barchart.com
ProQR reports positive Phase 1 data for AX-0810 in healthy volunteers - Investing.com Nigeria
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement - markets.businessinsider.com
ProQR Therapeutics Says Phase 1 Trial of Liver Drug Candidate Meets Primary Endpoint - marketscreener.com
ProQR Therapeutics Prices $50 Million Underwritten Registered Direct Offering - marketscreener.com
ProQR Reports Positive Phase 1 Data Validating Axiomer RNA Editing Platform - TipRanks
ProQR Therapeutics NV announced that its investigational therapy AX-422 for mucopolysaccharidosis type I (MPS1) is expected to submit a Clinical Trial Application (CTA) in early 2027. - Bitget
1.16%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):